Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

The Servier oncology pipeline in 2017.

Therasse P, Perron B, Novack SA, Abastado JP.

Future Oncol. 2017 Jul;13(17):1527-1536. doi: 10.2217/fon-2017-0129. Epub 2017 Apr 21.

2.

Servier's pipeline in oncology: moving from research to patients.

Therasse P, Abastado JP.

Future Oncol. 2016 Mar;12(5):589-94. doi: 10.2217/fon.15.363. Epub 2016 Jan 14. No abstract available.

3.

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.

Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V.

Gut. 2017 Feb;66(2):342-351. doi: 10.1136/gutjnl-2015-310814. Epub 2015 Dec 15.

4.

Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma.

Pin YK, Khoo K, Tham M, Karwai T, Hwee TC, Puaux AL, Phua ML, Kato M, Angeli V, Abastado JP.

Oncotarget. 2015 Dec 29;6(42):44806-18. doi: 10.18632/oncotarget.6326.

5.

HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma.

Xue Y, Toh SY, He P, Lim T, Lim D, Pang CL, Abastado JP, Thierry F.

Oncotarget. 2015 Oct 27;6(33):34979-91. doi: 10.18632/oncotarget.5512.

6.

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.

Thoreau M, Penny HL, Tan K, Regnier F, Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado JP, Tartour E, Trautmann A, Bercovici N.

Oncotarget. 2015 Sep 29;6(29):27832-46. doi: 10.18632/oncotarget.4940.

7.

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.

Ho V, Lim TS, Lee J, Steinberg J, Szmyd R, Tham M, Yaligar J, Kaldis P, Abastado JP, Chew V.

Oncotarget. 2015 Sep 29;6(29):27252-66. doi: 10.18632/oncotarget.4583.

8.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

9.

Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment.

Tan KW, Evrard M, Tham M, Hong M, Huang C, Kato M, Prevost-Blondel A, Donnadieu E, Ng LG, Abastado JP.

Oncoimmunology. 2015 Feb 25;4(2):e978709. eCollection 2015 Feb.

10.

Tumor-Immune interactions: implications for cancer therapy.

Tham M, Abastado JP.

Cell Cycle. 2015;14(9):1347-8. doi: 10.1080/15384101.2015.1032641. No abstract available.

11.

Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma.

Tham M, Khoo K, Yeo KP, Kato M, Prevost-Blondel A, Angeli V, Abastado JP.

Oncotarget. 2015 Sep 8;6(26):22857-68.

12.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

13.

Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation.

Tham M, Tan KW, Keeble J, Wang X, Hubert S, Barron L, Tan NS, Kato M, Prevost-Blondel A, Angeli V, Abastado JP.

Oncotarget. 2014 Dec 15;5(23):12027-42.

14.

Mapping of HPV transcripts in four human cervical lesions using RNAseq suggests quantitative rearrangements during carcinogenic progression.

Chen J, Xue Y, Poidinger M, Lim T, Chew SH, Pang CL, Abastado JP, Thierry F.

Virology. 2014 Aug;462-463:14-24. doi: 10.1016/j.virol.2014.05.026. Epub 2014 Jun 14.

15.

[The early steps of the metastatic process].

Hubert S, Abastado JP.

Med Sci (Paris). 2014 Apr;30(4):378-84. doi: 10.1051/medsci/20143004010. Epub 2014 May 5. Review. French.

16.

Negative contrast Cerenkov luminescence imaging of blood vessels in a tumor mouse model using [68Ga]gallium chloride.

Steinberg JD, Raju A, Chandrasekharan P, Yang CT, Khoo K, Abastado JP, Robins EG, Townsend DW.

EJNMMI Res. 2014 Mar 8;4(1):15. doi: 10.1186/2191-219X-4-15.

17.

Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG.

Nat Genet. 2014 Jan;46(1):24-32. doi: 10.1038/ng.2847. Epub 2013 Dec 8.

18.

Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D.

Tan KW, Chong SZ, Wong FH, Evrard M, Tan SM, Keeble J, Kemeny DM, Ng LG, Abastado JP, Angeli V.

Blood. 2013 Nov 21;122(22):3666-77. doi: 10.1182/blood-2012-11-466532. Epub 2013 Oct 10.

PMID:
24113869
19.
20.

In silico modeling of cancer cell dissemination and metastasis.

Wai LE, Narang V, Gouaillard A, Ng LG, Abastado JP.

Ann N Y Acad Sci. 2013 May;1284:71-4. doi: 10.1111/nyas.12077.

PMID:
23651197
21.

Loss of HPV16 E2 Protein Expression Without Disruption of the E2 ORF Correlates with Carcinogenic Progression.

Xue Y, Lim D, Zhi L, He P, Abastado JP, Thierry F.

Open Virol J. 2012;6:163-72. doi: 10.2174/1874357901206010163. Epub 2012 Dec 28.

22.

Detection, enumeration, and characterization of immune cells infiltrating melanoma tumors.

Toh B, Nardin A, Dai X, Keeble J, Chew V, Abastado JP.

Methods Mol Biol. 2013;961:261-77. doi: 10.1007/978-1-62703-227-8_17.

PMID:
23325650
23.

Myeloid cells: Prime drivers of tumor progression.

Toh B, Toh B, Abastado JP, Abastado JP.

Oncoimmunology. 2012 Nov 1;1(8):1360-1367.

24.

Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.

Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP.

J Natl Cancer Inst. 2012 Dec 5;104(23):1796-807. doi: 10.1093/jnci/djs436. Epub 2012 Nov 29.

25.

Immune microenvironment in tumor progression: characteristics and challenges for therapy.

Chew V, Toh HC, Abastado JP.

J Oncol. 2012;2012:608406. doi: 10.1155/2012/608406. Epub 2012 Aug 8.

26.

How to develop better screens for anti-cancer therapies?

Hong M, Abastado JP.

Oncoimmunology. 2012 May 1;1(3):383-384.

27.

Selection of Mesenchymal-Like Metastatic Cells in Primary Tumors - An in silico Investigation.

Narang V, Wong SY, Leong SR, Harish B, Abastado JP, Gouaillard A.

Front Immunol. 2012 Apr 27;3:88. doi: 10.3389/fimmu.2012.00088. eCollection 2012.

28.

The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor.

Abastado JP.

Cancer Res. 2012 May 1;72(9):2159-61. doi: 10.1158/0008-5472.CAN-11-3538. Review.

29.

Expansion of cortical and medullary sinuses restrains lymph node hypertrophy during prolonged inflammation.

Tan KW, Yeo KP, Wong FH, Lim HY, Khoo KL, Abastado JP, Angeli V.

J Immunol. 2012 Apr 15;188(8):4065-80. doi: 10.4049/jimmunol.1101854. Epub 2012 Mar 19.

30.

Immune predictors of cancer progression.

Toh B, Chew V, Dai X, Khoo K, Tham M, Wai LE, Hubert S, Velumani S, Zhi L, Huang C, Abastado JP.

Immunol Res. 2012 Sep;53(1-3):229-34. doi: 10.1007/s12026-012-8288-4. Review.

PMID:
22407576
31.

Tumor-infiltrating granulocytic cells promote cancer cell dissemination.

Toh B, Abastado J.

Ecancermedicalscience. 2012;6:241. doi: 10.3332/ecancer.2012.241. Epub 2012 Jan 16.

32.

A comparison of imaging techniques to monitor tumor growth and cancer progression in living animals.

Puaux AL, Ong LC, Jin Y, Teh I, Hong M, Chow PK, Golay X, Abastado JP.

Int J Mol Imaging. 2011;2011:321538. doi: 10.1155/2011/321538. Epub 2011 Nov 10.

33.

Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.

Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP.

PLoS Biol. 2011 Sep;9(9):e1001162. doi: 10.1371/journal.pbio.1001162. Epub 2011 Sep 27.

34.

Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prévost-Blondel A, Avril MF, Nardin A, Abastado JP.

Cancer Res. 2011 Nov 15;71(22):6997-7009. doi: 10.1158/0008-5472.CAN-11-1466. Epub 2011 Sep 26.

35.

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.

Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP.

Gut. 2012 Mar;61(3):427-38. doi: 10.1136/gutjnl-2011-300509. Epub 2011 Sep 19.

36.

Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.

Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prévost-Blondel A.

J Invest Dermatol. 2011 Sep;131(9):1896-905. doi: 10.1038/jid.2011.128. Epub 2011 Jun 9.

37.

T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma.

Lengagne R, Pommier A, Caron J, Douguet L, Garcette M, Kato M, Avril MF, Abastado JP, Bercovici N, Lucas B, Prévost-Blondel A.

PLoS One. 2011;6(5):e20235. doi: 10.1371/journal.pone.0020235. Epub 2011 May 25.

38.

Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.

Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Desprès P, Wang CI, Nardin A.

J Immunol. 2011 Mar 1;186(5):3258-64. doi: 10.4049/jimmunol.1003139. Epub 2011 Jan 28.

39.

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prévost-Blondel A, Chow P, Yang H, Abastado JP.

J Clin Invest. 2010 Jun;120(6):2030-9. doi: 10.1172/JCI42002. Epub 2010 May 24.

40.

Macrophage polarization to a unique phenotype driven by B cells.

Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, Wang X, Abastado JP, Lam KP, Biswas SK.

Eur J Immunol. 2010 Aug;40(8):2296-307. doi: 10.1002/eji.200940288.

41.

Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.

Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A.

J Hepatol. 2010 Mar;52(3):370-9. doi: 10.1016/j.jhep.2009.07.013. Epub 2009 Aug 3.

PMID:
19720422
42.

Macrophages and cancer.

Nardin A, Abastado JP.

Front Biosci. 2008 May 1;13:3494-505. Review.

PMID:
18508451
43.

Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases.

Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prévost-Blondel A.

J Immunol. 2008 Jan 1;180(1):130-7.

44.

Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.

Faure O, Graff-Dubois S, Alves PM, Cornet S, Duffour MT, Scardino A, Gross DA, Miconnet I, Salcedo M, Chouaib S, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Oncol Rep. 2007 Mar;17(3):679-85.

PMID:
17273751
45.

DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.

Ceccaldi PE, Delebecque F, Prevost MC, Moris A, Abastado JP, Gessain A, Schwartz O, Ozden S.

J Virol. 2006 May;80(10):4771-80.

46.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP.

Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review.

PMID:
16529542
47.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
48.
49.

Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.

Nobile C, Petit C, Moris A, Skrabal K, Abastado JP, Mammano F, Schwartz O.

J Virol. 2005 May;79(9):5386-99.

50.

Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector.

Babon A, Almunia C, Boccaccio C, Beaumelle B, Gelb MH, Ménez A, Maillère B, Abastado JP, Salcedo M, Gillet D.

FEBS Lett. 2005 Mar 14;579(7):1658-64.

Supplemental Content

Loading ...
Support Center